Compare
CRISPR Therapeutics AG vs Surrozen, Inc. vs CG Oncology, Inc. vs Ocugen, Inc.
| Latest fiscal year | CRISPR Therapeutics AG CRSP | Surrozen, Inc. SRZN | CG Oncology, Inc. CGON | Ocugen, Inc. OCGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.51M | $3.48M | $4.04M | $4.41M |
| Revenue growth (YoY) | -90.6% | -67.4% | +254.7% | +8.8% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$581.60M | -$242.03M | -$161.00M | -$67.85M |
| EPS (Diluted) | -$6.47 | -$32.37 | -$2.08 | n/a |
| Operating cash flow | -$345.01M | -$30.24M | -$132.35M | -$56.96M |
| Free cash flow | -$345.93M | -$30.37M | -$132.48M | -$57.15M |
| Cash & equivalents | $347.56M | $89.25M | $32.49M | n/a |
| Total assets | $2.27B | $98.73M | $791.59M | $43.52M |
| Total liabilities | $343.43M | $286.49M | $38.99M | $55.68M |
| Shareholders' equity | $1.92B | -$187.76M | $752.60M | -$12.17M |
| Return on year-end equity | -30.3% | n/a | -21.4% | n/a |
| Shares outstanding | 95.89M | 9.78M | 80.69M | 312.38M |
Revenue, most recent five fiscal years
| Fiscal year | CRISPR Therapeutics AG | Surrozen, Inc. | CG Oncology, Inc. | Ocugen, Inc. |
|---|---|---|---|---|
| Latest | $3.51M Ended 2025-12-31 | $3.48M Ended 2025-12-31 | $4.04M Ended 2025-12-31 | $4.41M Ended 2025-12-31 |
| 1 year earlier | $37.31M Ended 2024-12-31 | $10.65M Ended 2024-12-31 | $1.14M Ended 2024-12-31 | $4.05M Ended 2024-12-31 |
| 2 years earlier | $371.21M Ended 2023-12-31 | $0 Ended 2023-12-31 | $204.0K Ended 2023-12-31 | $6.04M Ended 2023-12-31 |
| 3 years earlier | $1.20M Ended 2022-12-31 | $12.50M Ended 2022-12-31 | n/a | $2.49M Ended 2022-12-31 |
| 4 years earlier | $914.96M Ended 2021-12-31 | $0 Ended 2021-12-31 | n/a | n/a |